Microbial Dynamics in Inflammatory Bowel Disease

Inflammatory Bowel Disease (IBD) is characterised by chronic inflammation of the gastrointestinal tract, encompassing Crohn’s disease and ulcerative colitis. A key driver of pathogenesis is the dynamic interplay between the host immune system and the intestinal microbiota. In a healthy gut, a diverse microbial community contributes to mucosal homeostasis through production of short-chain fatty acids, regulation of epithelial barrier function and modulation of immune responses. In IBD, this balance is disrupted, leading to dysbiosis characterised by reduced microbial diversity, loss of beneficial commensals and the emergence of pathobionts—resident microbes with the potential to trigger inflammation. These alterations affect metabolic pathways, including fatty acid metabolism and oxidative stress responses, and reshape the mucosal environment, perpetuating a cycle of barrier dysfunction and immune activation. Environmental factors such as diet and antibiotic exposure further influence these microbial shifts, underscoring the complexity of host–microbe crosstalk. Understanding microbial dynamics offers a route towards precision medicine, with interventions targeting microbial composition or function to restore equilibrium, predict therapeutic response and improve patient outcomes worldwide.

Research from Nature Portfolio

Recent studies have mapped tissue-specific host–microbe interactions in patients with IBD, revealing discrete inflammation-associated gene-taxa modules that vary with clinical phenotype and treatment. For instance, shifts in Bifidobacterium abundance correlate with genes controlling fatty acid metabolism, whereas Bacteroides species align with metallothionein signalling in inflamed mucosa. Distinct microbial associations have been observed in fibrostenotic Crohn’s disease and among patients receiving TNF-α antagonists, highlighting opportunities for microbiota-directed precision therapy. Foundational work in animal models has further demonstrated that dietary patterns typical of Western populations induce mucosal dysbiosis by promoting expansion of pro-inflammatory Proteobacteria, diminishing short-chain fatty acid–producing taxa and reducing expression of epithelial SCFA receptors. These diet-induced ecological changes increase susceptibility to adherent-invasive E. coli colonisation and intestinal inflammation, suggesting that modulation of host receptors and microbial niches could form the basis of new prophylactic and therapeutic strategies.

Microbial Dynamics in Inflammatory Bowel Disease publication trend

The graph below shows the total number of articles in microbial dynamics in inflammatory bowel disease across all publications each year (not limited to Nature Index journals).

Technical terms

Dysbiosis: A disturbance in the composition and function of the gut microbiota, often marked by reduced diversity and loss of beneficial species.

Pathobiont: A normally commensal microbe that, under specific conditions, acquires or reveals pathogenic properties contributing to disease.

Mucosal barrier: The epithelial and underlying immune cell layer lining the intestine that regulates interactions between luminal microbes and host tissue.

Short-chain fatty acids (SCFAs): Metabolites produced by microbial fermentation of dietary fibres that support epithelial integrity and modulate immune function.

References

1. Pathobionts in Inflammatory Bowel Disease: Origins, Underlying Mechanisms, and Implications for Clinical Care. Gastroenterology (2023).
2. Mucosal host-microbe interactions associate with clinical phenotypes in inflammatory bowel disease. Nature Communications (2024).
3. The Gut Microbiota Affects Anti‐TNF Responsiveness by Activating the NAD+ Salvage Pathway in Ulcerative Colitis. Advanced Science (2024).
4. Western diet induces a shift in microbiota composition enhancing susceptibility to Adherent-Invasive E. coli infection and intestinal inflammation.. Scientific Reports (2016).